An assessment of the clinical utility of echocardiography criteria in a Tertiary Health Center

Ehimwenma J. Ogbemudia, Wilson E. Sadoh¹

Departments of Medicine, 1Child Health, University of Benin Teaching Hospital, Benin City, Edo State, Nigeria

ABSTRACT

Background: The rising prevalence of cardiovascular diseases in the population has increased the demand for cardiovascular imaging procedures (specifically echocardiography) in our center. Aim: To determine the percentage of appropriate indications for echocardiography. Materials and Methods: This was a prospective study conducted over a period of 1 year in the Department of Medicine of a Tertiary Health Care Center. The clinical diagnoses by the referring clinician and the indications (specific reasons for the study) for the echocardiography were consecutively recorded. The age and gender of the patients were also recorded. The indications were given a score of one to nine according to the revised appropriate use criteria of the American College of Cardiology Foundation and the American Society of Echocardiography (ASE). These indications were then classified into appropriate, inappropriate or uncertain based on the score. (1-3)-inappropriate use, (4-6) were derived. **Results:** There were 25 indications, 16 (64%) were appropriate, 6 (24%) were inappropriate and three (12%) were rated as uncertain. **Conclusion:** Sixty-four percent of the indications for echocardiography are appropriate for the procedure. This implies that the criteria for echocardiography are yet to be fully implemented resulting in overutilization of the procedure.

Address for correspondence: Dr. Ehimwenma J. Ogbemudia, Department of Medicine, University of Benin Teaching Hospital, Benin City, Edo State, Nigeria. E-mail: ogbemudiaehi@yahoo.com

Key words: Echocardiography, criteria, utility

INTRODUCTION

Echocardiography is a noninvasive, diagnostic cardiovascular imaging procedure. It is the most commonly utilized imaging technique in the evaluation of patients with suspected or known cardiovascular disease besides chest radiograph.¹

It is useful in determining structural and functional cardiac statuses. It is also of prognostic value and a research tool.²

Echocardiography was invented by Elder and Hertz in 1954, but it was introduced in Nigeria in the midseventies by Lawal *et al.*³ Since then the practice of echocardiography has grown phenomenally and it is now routinely performed in most tertiary health

| Access this | article online |
|----------------------|----------------------------------|
| Quick Response Code: | Website |
| | www.nigeriamedj.com |
| | DOI: 10.4103/0300-1652.169706 |

institution across the country. It has a high degree of sensitivity and specificity when performed by experienced personnel.

Several professional bodies have published guidelines in an attempt to ensure its rational use. The American College of Cardiology Foundation (ACCF) and the American Society of Echocardiography (ASE) published the first appropriate use criteria (AUC) for transthoracic echocardiography in 2007 which was recently revised in 2011.⁴

In recent years, there has been a remarkable increase in the demand for all forms of cardiovascular imaging worldwide^{5,6} specifically echocardiography in our institution. This increase in utilization has the potential for misuse, which invariably increases the costs to the patients, health insurance companies, and the hospital.

Several studies on echocardiography have been conducted in the country, but none has appraised its use in terms of the appropriateness of the indications for the procedure. It is, therefore, expedient to assess the clinical implementation of the criteria for echocardiography.

MATERIALS AND METHODS

This was a prospective study, and the protocol was approved by the hospitals research and ethics committee. All the echocardiography studies performed within 1-year were consecutively enrolled. The variables included the age, gender, and the clinical scenario (diagnosis by the referring clinician). The indications (specific reasons for ordering the procedure) were also recorded.

The studies were then categorized based on the clinical scenario. Each of the indications was scored on a scale of 1-9 according to the revised AUC of the ACCF/ASE. These scores were then used to rate the indications as appropriate, inappropriate, or uncertain.

These criteria were applied in this study because there are no indigenous criteria for echocardiography in our locale.

Score of 1-3 (inappropriate indication)

Echocardiography is not generally acceptable and not a reasonable approach for the indication.⁷

Score of 4-6 (uncertain indication)

Echocardiography may be generally acceptable and may be a reasonable approach for the indication. More research and/or patient information is needed to classify the test definitively.⁷

Score of 7-9 (appropriate indication)

Echocardiography is generally acceptable and is a reasonable approach for the indication. That is a study in which the expected incremental information, combined with clinical judgment, exceeds the expected negative consequence by a sufficiently wide margin for a specific indication.

The revised AUC criteria derived its indications from common clinical applications or anticipated uses, as well as from current practice guidelines and are regularly updated based on evidence from studies examining the implementation of the original AUC.

The criteria were based on five broad groups of indications regarding the possible use of echocardiography:

- 1. For initial diagnosis;
- 2. To guide therapy or management, regardless of symptom status;
- 3. To evaluate a change in clinical status or cardiac examination;
- 4. For early follow-up without change in clinical status; and
- 5. For late follow-up without change in clinical status.

In general, the indications were rated as appropriate when echocardiography was requested for initial evaluation of structure and function, a change in clinical status or when the results of the echocardiogram are anticipated to change patient management. Routine testing when there was no change in clinical status or when results of testing were unlikely to modify management were rated as inappropriate or uncertain.

Statistical analysis

Data were analyzed with SPSS version 16 (SPSS Inc, Chicago). The mean age of the patients was derived, and the frequency of the gender determined. The percentage of the appropriate indications was determined by the number of appropriate indications/total number of indications × 100. The percentages of the inappropriate and uncertain indications were also determined.

RESULTS

A total of 796 studies were recorded, 21 were excluded because of inadequate data while 775 were analyzed. The mean age of the patients was 43.28 ± 27.2 years. Echocardiography was requested for in the setting of 15 different clinical scenarios. There were 25 indications. 16 (64 %) of the indications were appropriate, 6 (24%) were inappropriate and 3 (12%) were rated as uncertain. Of the 775 studies 605 (78.1%) were appropriate studies, 146 (18.8%) were inappropriate while 24 (3.1%) were uncertain.



Figure 1: Frequency of clinical scenario. ACH – Adult congenital heart disease; ARY – Arrhythmias; CMP – Cardiomyopathy; CP – Chest pain; CVA – Cerebrovascular disease; HF – Heart failure; HT/HHD – Hypertension/hypertensive heart disease; IHD – Ischemic heart disease; PAL – Palpitation; PCD - Pericardial disease; PE – Pulmonary embolism; POA – Perioperative assessment; SCP – Syncope; SCR - Screening for cardiovascular disease; VHD – Valvular heart disease

| Clinical scenario/reason for test (indications)Scoren (%)Heart failure9 (A)140 (18.1)Initial evaluation of heart failure8 (A)74 (9.5)Hypertension/hypertensive heart disease8 (A)150 (19.3)Routine evaluation of hypertension3 (I)91 (11.7)Initial evaluation of hypertensive heart disease8 (A)150 (19.3)Routine follow-up of known hypertensive heart4 (U)14 (1.8)disease4 (U)14 (1.8)Preoperative assessment9 (A)50 (6.5)features of cardiovascular disease2 (I)26 (3.3)function2 (I)26 (3.3)function2 (I)26 (3.3)function9 (A)40 (5.2)Routine preoperative evaluation of cardiac9 (A)40 (5.2)Routine surveillance of valvular heart disease9 (A)40 (5.2)Routine surveillance of valvular heart disease6 (U)7 (0.9)Cerebrovascular disease9 (A)18 (2.3)Cardiomyopathy9 (A)16 (2.1)Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Christ painCinical features suggestive of cardiac etiology9 (A)10 (1.3)Routine surveillance of known cardiomyopathy9 (A)10 (1.3)Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Christ pain210 (1.3)10 (1.3)Routine surveillance of known cardiomyopathy2 (I)5 (0.6)Palitation210 (5.6) |
|---|
| Heart failure9 (A)140 (18.1)Acute deterioration of heart failure8 (A)74 (9.5)Hypertension/hypertensive heart disease8 (A)74 (9.5)Routine evaluation of hypertension3 (I)91 (11.7)Initial evaluation of hypertensive heart disease8 (A)150 (19.3)Routine follow-up of known hypertensive heart4 (U)14 (1.8)disease4 (U)14 (1.8)Preioperative assessment9 (A)50 (6.5)features of cardiovascular disease2 (I)26 (3.3)Routine preoperative evaluation of cardiac2 (I)26 (3.3)function123 (3.0)23 (3.0)Ischemic heart disease9 (A)40 (5.2)Routine surveillance of valvular heart disease9 (A)31 (4.0)Pericardial disease9 (A)18 (2.3)Cardiomyopathy9 (A)16 (2.1)Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Christ evaluation of cardiac etiology9 (A)16 (2.1)Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Christ evaluation of cardiac etiology9 (A)16 (2.1)Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Christ evaluation of chest pain2 (I)5 (0.6)Palpitation10 (1.3)10 (1.3)Routine surveillance of cardiac etiology9 (A)10 (1.3)Routine surveillance of cardiac etiology9 (A)10 (1.3)Routine evaluation of chest pain2 (I)5 (0.6)< |
| Initial evaluation of heart failure9 (A)140 (18.1)Acute deterioration of heart failure8 (A)74 (9.5)Hypertension/hypertensive heart disease8 (A)150 (19.3)Routine evaluation of hypertensive heart disease8 (A)150 (19.3)Routine follow-up of known hypertensive heart4 (U)14 (1.8)disease4 (U)14 (1.8)Perioperative assessment9 (A)50 (6.5)Features of cardiovascular disease2 (I)26 (3.3)Routine properative evaluation of cardiac2 (I)26 (3.3)function123 (3.0)23 (3.0)Initial evaluation of suspected valvular heart disease9 (A)40 (5.2)Routine surveillance of valvular heart disease9 (A)31 (4.0)Pericardial disease9 (A)18 (2.3)Cardiomyopathy9 (A)16 (2.1)Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Chincal features suggestive of cardiac etiology9 (A)16 (2.1)Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Chincal features suggestive of cardiac etiology9 (A)16 (2.1)Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Chincal features suggestive of cardiac etiology9 (A)10 (1.3)Routine evaluation of chest pain2 (I)5 (0.6)Pajitation101.31.3Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Chincal features suggestive of cardiac etiology9 (A)10 (1. |
| Acute deterioration of heart failure8 (A)74 (9.5)Hypertension/hypertensive heart disease3 (I)91 (11.7)Initial evaluation of hypertensive heart disease8 (A)150 (19.3)Routine follow-up of known hypertensive heart4 (U)14 (1.8)disease14 (U)14 (1.8)Preioperative assessment9 (A)50 (6.5)features of cardiovascular disease2 (I)26 (3.3)Routine preoperative evaluation of cardiac2 (I)26 (3.3)function2 (I)26 (3.3)10 (5.2)Initial evaluation of ventricular function after acute9 (A)23 (3.0)coronary syndrome9 (A)23 (3.0)23 (3.0)Valvular heart disease6 (U)7 (0.9)Cerebrovascular disease9 (A)31 (4.0)Pericardial disease9 (A)31 (4.0)Pericardial disease9 (A)16 (2.1)Routine surveillance of valvular heart disease9 (A)16 (2.1)Routine surveillance of known cardiomyopathy9 (A)16 (2.1)Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Clinical features suggestive of cardiac etiology9 (A)10 (1.3)Routine surveillance of chrom cardiomyopathy5 (U)3 (0.4)Clinical features suggestive of cardiac etiology9 (A)10 (1.3)Routine surveillance of known cardiomyopathy2 (I)5 (0.6)Palpitation2 (I)5 (0.6)2 |
| Hypertension/hypertensive heart disease3 (I)91 (11.7)Initial evaluation of hypertensive heart disease8 (A)150 (19.3)Routine follow-up of known hypertensive heart4 (U)14 (1.8)disease214 (1.8)Perioperative assessment9 (A)50 (6.5)features of cardiovascular disease2 (I)26 (3.3)Routine preoperative evaluation of cardiac2 (I)26 (3.3)function223 (3.0)Ischemic heart disease9 (A)23 (3.0)coronary syndrome9 (A)23 (3.0)Valvular heart disease9 (A)40 (5.2)Routine surveillance of valvular heart disease9 (A)31 (4.0)Pericardial disease9 (A)31 (4.0)Pericardial disease9 (A)16 (2.1)Routine surveillance of known cardiomyopathy9 (A)16 (2.1)Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Clinical features suggestive of cardiac etiology9 (A)10 (1.3)Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Clinical features suggestive of cardiac etiology9 (A)10 (1.3)Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Clinical features suggestive of cardiac etiology9 (A)10 (1.3)Routine surveillance of chromy cardiomyopathy5 (U)5 (0.6)Palpitation2 (I)5 (0.6)2 (I) |
| Routine evaluation of hypertension3 (l)91 (11.7)Initial evaluation of hypertensive heart disease8 (A)150 (19.3)Routine follow-up of known hypertensive heart4 (U)14 (1.8)disease2 (U)14 (1.8)Preioperative assessment9 (A)50 (6.5)features of cardiovascular disease2 (I)26 (3.3)function2 (I)26 (3.3)function2 (I)26 (3.3)lischemic heart disease9 (A)23 (3.0)coronary syndrome9 (A)23 (3.0)Valvular heart disease6 (U)7 (0.9)Cerebrovascular disease9 (A)31 (4.0)Pericardial disease9 (A)31 (4.0)Pericardial disease9 (A)18 (2.3)Cardiomyopathy9 (A)16 (2.1)Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Clinical features suggestive of cardiac etiology9 (A)10 (1.3)Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Clinical features suggestive of cardiac etiology9 (A)10 (1.3)Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Clinical features suggestive of cardiac etiology9 (A)10 (1.3)Routine surveillance of chrome cardiomyopathy5 (U)5 (0.6)Palpitation2 (I)5 (0.6) |
| Initial evaluation of hypertensive heart disease8 (A)150 (19.3)Routine follow-up of known hypertensive heart disease4 (U)14 (1.8)Perioperative assessment9 (A)50 (6.5)Pereoperative evaluation of cardiac function with features of cardiovascular disease9 (A)50 (6.5)Routine preoperative evaluation of cardiac function2 (I)26 (3.3)Ischemic heart disease2 (I)26 (3.3)Evaluation of ventricular function after acute coronary syndrome9 (A)23 (3.0)Valvular heart disease9 (A)40 (5.2)Routine surveillance of valvular heart disease Stroke with suspected cardiac etiology9 (A)31 (4.0)Pericardial disease Suspected pericardial disease9 (A)18 (2.3)Cardiomyopathy Initial evaluation of cardiomyopathy9 (A)16 (2.1)Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Chest pain Clinical features suggestive of cardiac etiology9 (A)10 (1.3)Routine evaluation of chest pain2 (I)5 (0.6)Palpitation2 (I)5 (0.6) |
| Routine follow-up of known hypertensive heart disease4 (U)14 (1.8)Perioperative assessment9 (A)50 (6.5)Pereoperative evaluation of cardiac function with features of cardiovascular disease9 (A)50 (6.5)Routine preoperative evaluation of cardiac function2 (I)26 (3.3)Ischemic heart disease9 (A)23 (3.0)Evaluation of ventricular function after acute coronary syndrome9 (A)23 (3.0)Valvular heart disease9 (A)40 (5.2)Routine surveillance of valvular heart disease Stroke with suspected cardiac etiology9 (A)31 (4.0)Pericardial disease9 (A)18 (2.3)Cardiomyopathy Initial evaluation of cardiomyopathy9 (A)16 (2.1)Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Clinical features suggestive of cardiac etiology9 (A)10 (1.3)Routine surveillance of known cardiomyopathy5 (U)3 (0.4) |
| Perioperative assessment9 (A)50 (6.5)Preoperative evaluation of cardiac function with features of cardiovascular disease9 (A)50 (6.5)Routine preoperative evaluation of cardiac function2 (I)26 (3.3)Ischemic heart disease2 (I)26 (3.3)Evaluation of ventricular function after acute coronary syndrome9 (A)23 (3.0)Valvular heart disease9 (A)23 (3.0)Initial evaluation of suspected valvular heart disease Butine surveillance of valvular heart disease9 (A)40 (5.2)Routine surveillance of valvular heart disease6 (U)7 (0.9)Cerebrovascular disease9 (A)31 (4.0)Pericardial disease9 (A)18 (2.3)Cardiomyopathy9 (A)16 (2.1)Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Clinical features suggestive of cardiac etiology9 (A)10 (1.3)Routine evaluation of chest pain2 (I)5 (0.6)Palpitation2 (I)5 (0.6) |
| Preoperative evaluation of cardiac function with features of cardiovascular disease9 (A)50 (6.5)Routine preoperative evaluation of cardiac function2 (I)26 (3.3)Ischemic heart disease2 (I)26 (3.3)Evaluation of ventricular function after acute coronary syndrome9 (A)23 (3.0)Valvular heart disease9 (A)23 (3.0)Initial evaluation of suspected valvular heart disease function9 (A)40 (5.2)Routine surveillance of valvular heart disease6 (U)7 (0.9)Cerebrovascular disease9 (A)31 (4.0)Pericardial disease9 (A)18 (2.3)Cardiomyopathy9 (A)16 (2.1)Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Chinical features suggestive of cardiac etiology9 (A)10 (1.3)Routine evaluation of chest pain2 (I)5 (0.6)Palpitation2 (I)5 (0.6) |
| Routine preoperative evaluation of cardiac function2 (I)26 (3.3)Ischemic heart disease23 (3.0)Ischemic heart disease9 (A)23 (3.0)Coronary syndrome9 (A)23 (3.0)Valvular heart disease9 (A)40 (5.2)Routine surveillance of valvular heart disease6 (U)7 (0.9)Cerebrovascular disease9 (A)31 (4.0)Pericardial disease9 (A)18 (2.3)Cardiomyopathy9 (A)16 (2.1)Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Chest pain210 (1.3)Routine surveillance of cardiac etiology9 (A)10 (1.3)Routine surveillance of cardiac etiology9 (A)10 (1.3)Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Chest pain210 (1.3)Routine evaluation of chest pain2 (I)5 (0.6)Palpitation210 (1.3) |
| Ischemic heart disease9 (A)23 (3.0)Evaluation of ventricular function after acute coronary syndrome9 (A)23 (3.0)Valvular heart disease9 (A)40 (5.2)Routine surveillance of valvular heart disease6 (U)7 (0.9)Cerebrovascular disease6 (U)7 (0.9)Stroke with suspected cardiac etiology9 (A)31 (4.0)Pericardial disease9 (A)18 (2.3)Cardiomyopathy9 (A)16 (2.1)Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Chest pain210 (1.3)Routine evaluation of chest pain2 (I)5 (0.6)Palpitation2 (I)5 (0.6) |
| Evaluation of ventricular function after acute coronary syndrome9 (A)23 (3.0)Valvular heart disease9 (A)40 (5.2)Initial evaluation of suspected valvular heart disease6 (U)7 (0.9)Cerebrovascular disease6 (U)7 (0.9)Cerebrovascular disease9 (A)31 (4.0)Pericardial disease9 (A)18 (2.3)Cardiomyopathy9 (A)16 (2.1)Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Chest pain2 (I)5 (0.6)Papitation2 (I)5 (0.6) |
| coronary syndromeValvular heart disease9 (A)40 (5.2)Noutine surveillance of valvular heart disease6 (U)7 (0.9)Cerebrovascular disease6 (U)7 (0.9)Cerebrovascular disease9 (A)31 (4.0)Pericardial disease9 (A)31 (4.0)Pericardial disease9 (A)18 (2.3)Cardiomyopathy9 (A)16 (2.1)Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Chest pain710 (1.3)Routine evaluation of chest pain2 (I)5 (0.6)Palpitation10 (1.3)10 (1.3) |
| Valvular heart disease9 (A)40 (5.2)Routine surveillance of valvular heart disease6 (U)7 (0.9)Cerebrovascular disease5 (U)7 (0.9)Stroke with suspected cardiac etiology9 (A)31 (4.0)Pericardial disease9 (A)18 (2.3)Cardiomyopathy9 (A)16 (2.1)Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Chest pain710 (1.3)Routine evaluation of chest pain2 (I)5 (0.6)Palpitation910 (1.3) |
| Initial evaluation of suspected valvular heart disease9 (A)40 (5.2)Routine surveillance of valvular heart disease6 (U)7 (0.9)Cerebrovascular disease5 (U)31 (4.0)Pericardial disease9 (A)31 (4.0)Pericardial disease9 (A)18 (2.3)Cardiomyopathy9 (A)16 (2.1)Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Chest pain010 (1.3)Routine evaluation of chest pain2 (I)5 (0.6)Palpitation010 (1.3) |
| Routine surveillance of valvular heart disease6 (U)7 (0.9)Cerebrovascular diseaseStroke with suspected cardiac etiology9 (A)31 (4.0)Pericardial disease9 (A)18 (2.3)Cardiomyopathy9 (A)16 (2.1)Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Chest painClinical features suggestive of cardiac etiology9 (A)10 (1.3)Routine evaluation of chest pain2 (I)5 (0.6) |
| Cerebrovascular disease9 (A)31 (4.0)Stroke with suspected cardiac etiology9 (A)31 (4.0)Pericardial disease9 (A)18 (2.3)Cardiomyopathy9 (A)16 (2.1)Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Chest pain |
| Stroke with suspected cardiac etiology9 (A)31 (4.0)Pericardial disease9 (A)18 (2.3)Cardiomyopathy9 (A)16 (2.1)Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Chest pain710 (1.3)Routine evaluation of chest pain2 (I)5 (0.6)Palpitation910 (1.3) |
| Pericardial disease 9 (A) 18 (2.3) Suspected pericardial disease 9 (A) 18 (2.3) Cardiomyopathy 9 (A) 16 (2.1) Routine surveillance of known cardiomyopathy 5 (U) 3 (0.4) Chest pain 7 10 (1.3) Routine evaluation of chest pain 2 (I) 5 (0.6) |
| Suspected pericardial disease9 (A)18 (2.3)Cardiomyopathy9 (A)16 (2.1)Initial evaluation of cardiomyopathy9 (A)16 (2.1)Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Chest pain210 (1.3)Routine evaluation of chest pain2 (I)5 (0.6)Palpitation |
| Cardiomyopathy9 (A)16 (2.1)Initial evaluation of cardiomyopathy9 (A)16 (2.1)Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Chest pain2 (I)10 (1.3)Routine evaluation of chest pain2 (I)5 (0.6)Palpitation |
| Initial evaluation of cardiomyopathy9 (A)16 (2.1)Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Chest pain210 (1.3)Routine evaluation of chest pain2 (I)5 (0.6)Palpitation210 (1.3) |
| Routine surveillance of known cardiomyopathy5 (U)3 (0.4)Chest painClinical features suggestive of cardiac etiology9 (A)10 (1.3)Routine evaluation of chest pain2 (I)5 (0.6)PalpitationClinical features for the state of the state |
| Chest pain9 (A)10 (1.3)Clinical features suggestive of cardiac etiology9 (A)10 (1.3)Routine evaluation of chest pain2 (I)5 (0.6)Palpitation10 (1.3)10 (1.3) |
| Clinical features suggestive of cardiac etiology9 (A)10 (1.3)Routine evaluation of chest pain2 (I)5 (0.6)Palpitation |
| Routine evaluation of chest pain2 (I)5 (o.6)Palpitation |
| Palpitation |
| |
| Clinical features suggestive of cardiac etiology 9 (A) 14 (1.8) |
| Routine evaluation of palpitations 2 (I) 7 (0.9) |
| Arrhythmia |
| Atrial fibrillation 8 (A) 18 (2.3) |
| Infrequent atrial and ventricular premature complex 2 (I) 13 (1.7) |
| Frequent ventricular premature ectopic8 (A)7 (0.9) |
| Syncope |
| Syncope with symptoms suggestive of cardiac 9 (A) 6 (o.8) disease |
| Adult congenital heart disease |
| Initial evaluation of adult congenital heart disease 9 (A) 5 (0.6) |
| Screening |
| Screening for cardiac disease in first degree 9 (A) 3 (0.4) relatives of patients with genetic cardiac |
| Pulmonary embolism |
| To establish diagnosis in suspected pulmonary 2 (I) 4 (0.5) embolism |
| Total 775 (100) |

A – Appropriate; I – Inappropriate; U – Uncertain

DISCUSSION

The results show that sixty four percentage of the indications for echocardiography were appropriate for the procedure in our center. This is a modest result, for a tertiary hospital setting where the best medical practice should be the norm. The most likely explanation for this finding is that besides the specialist physician

(cardiologists), other clinicians also manage patients with cardiovascular diseases and as such request for echocardiography. This is due to the high prevalence of cardiovascular diseases in the population and the limited number of cardiologists. These noncardiologists are not conversant with the criteria for echocardiography and so more likely to misuse the procedure compared with the cardiac physician. The partial utility of the criteria for echocardiography invariably results in overutilization of the procedure.

In a study by Patil *et al.*,⁸ 82% of the indications were appropriate for echocardiography while Ballo *et al.*⁹ reported 80.3% in a study of 931 patients in a community hospital. These higher rates of appropriate indications can be attributed to better awareness and utility of the criteria for echocardiography. This is most probably due to the existence of indigenous criteria in their practice. Unfortunately, there are no similar local studies in the literature with which to compare our results.

The results also show that 24% of the indications were inappropriate this is lower than the appropriate indications but can be reduced further to ensure better use of echocardiography and management of patients and hospital's scarce resources. The inappropriate indications in the aforementioned studies were lower than that of this study because of their higher rate of appropriate indications.

Only 3 (12%) of the indications were rated as uncertain. The explanation is that the uncertain indications in the AUC criteria are primarily concerned about periodic surveillance or monitoring the progression of cardiac disease after the initial study. Patients usually do not show up for serial follow-up studies after the initial study except they have worsening symptoms. This may be due to financial constraint or lack of motivation.

The results show that echocardiography was most commonly requested for in the clinical setting of hypertension and heart failure [Figure 1]. This reflects the high prevalence of hypertension in the population. Heart failure is also common because most patients present to the hospital late in the course of the disease when the cardiac function has already been compromised. Ogah *et al.*¹⁰ reported a similar finding in their study of the use, problems, reproducibility, and potentials of echocardiography in Nigeria.

The two most common appropriate indications for echocardiography were an initial evaluation of hypertensive heart disease and heart failure (19.9% and 18.1%), respectively [Table 1]. Most of the inappropriate studies were due to the routine evaluation of hypertension and preoperative assessment of ventricular function even in the absence of evidence of cardiovascular disease [Table 1]. Other inappropriate indications include clinically insignificant arrhythmias such as occasional atrial or ventricular premature complexes.

All the indications reviewed in this study were captured in the AUC. This is not surprising as the revised AUC is an improvement on previous editions and covers more clinical scenarios than the previous editions.^{11,12}

One of the limitations of this study is that the criteria applied were developed in a different locale so it may not be fully applicable in our practice. The results cannot also be generalized to other tiers of healthcare delivery as the results may differ if conducted in a private hospital or secondary health care facility.

Proposed recommendations to improve the clinical implementation or the use of echocardiography include education of health care providers concerned with the management of cardiovascular diseases about the criteria for echocardiography. This will significantly reduce the number of inappropriate indications and studies. All requests for echocardiography should be screened for appropriateness of indication prior to the procedure.

CONCLUSION

Sixty-four percent of the indications for echocardiography were appropriate, which implies that the criteria for echocardiography are being utilized although, it is yet to be fully implemented. This has resulted in overutilization of the procedure. Institution of the recommendations mentioned above will further improve the clinical utility of the criteria and the use of echocardiography.

REFERENCES

- 1. Hillis GS, Bloomfield P. Basic transthoracic echocardiography. BMJ 2005;330:1432-6.
- Balogun MO, Urhogide GE, Ukoh VA, Adebayo RA. A preliminary audit of two-dimensional and Doppler echocardiographic service in a Nigerian tertiary private hospital. Niger J Med 1999;8:13-141.
- 3. Lawal SO, Falase AO. The effect of hypertension on the heart of adult Nigerians. Trop Cardiol 1988;14:153-7.
- American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear

Cardiology, Heart Failure Society of America, Heart Rhythm Society, *et al.* ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/ SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance American College of Chest Physicians. J Am Soc Echocardiogr 2011;24:229-67.

- 5. Pearlman AS, Ryan T, Picard MH, Douglas PS. Evolving trends in the use of echocardiography: A study of Medicare beneficiaries. J Am Coll Cardiol 2007;49:2283-91.
- Lucas FL, DeLorenzo MA, Siewers AE, Wennberg DE. Temporal trends in the utilization of diagnostic testing and treatments for cardiovascular disease in the United States, 1993-2001. Circulation 2006;113:374-9.
- Douglas PS, Khanderia B, Stainback RF, Weissman NJ, Brindis RG, Patel MR, *et al.* ACCF/ASE/ACEP/ASN/SCA/ SCCT/SCMR 2007 appropriateness criteria for transthoracic and transesophageal echocardiography: A Report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group. J Am Coll Cardiol 2007;50:187-204.
- Patil HR, Coggins TR, Kusnetzky LL, Main ML. Evaluation of appropriate use of transthoracic echocardiography in 1,820 consecutive patients using the 2011 revised appropriate use criteria for echocardiography. Am J Cardiol 2012;109:1814-7.
- Ballo P, Bandini F, Capecchi I, Chiodi L, Ferro G, Fortini A, et al. Application of 2011 American College of Cardiology Foundation/American Society Of Echocardiography appropriateness use criteria in hospitalized patients referred for transthoracic echocardiography in a community setting. J Am Soc Echocardiogr 2012;25:589-98.
- Ogah OS, Adebanjo AT, Otukoya AS, Jagusa TJ. Use, problems, reproducibility and potentials of echocardiography in Nigeria. Cardiovasc Ultrasound 2006;4:13.
- Bhatia RS, Carne DM, Picard MH, Weiner RB. Comparison of the 2007 and 2011 appropriate use criteria for transthoracic echocardiography in various clinical settings. J Am Soc Echocardiogr 2012;25:1162-9.
- Mansour IN, Razi RR, Bhave NM, Ward RP. Comparison of the updated 2011 appropriate use criteria for echocardiography to the original criteria for transthoracic, transesophageal, and stress echocardiography. J Am Soc Echocardiogr 2012;25:1153-61.

How to cite this article: Ogbemudia EJ, Sadoh WE. An assessment of the clinical utility of echocardiography criteria in a Tertiary Health Center. Niger Med J 2015;56:268-71.

Source of Support: Nil. Conflicts of Interest: None declared.